Related Experiment Video
Updated: Jul 6, 2026
07:23
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
Genetic mutations that prevent pain: implications for future pain medication.
1Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe-University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany.
Pharmacogenomics
|March 29, 2008
Summary
Genetic variations significantly influence pain perception and response to analgesics. Rare syndromes can prevent pain entirely, while common variants affect pain sensitivity and drug efficacy, impacting pain management strategies.
Area of Science:
- Genetics and Pain Research
- Pharmacogenomics
- Neuroscience
Background:
- Interindividual variability in pain therapy is partly explained by genetic polymorphisms.
- Specific genetic variants can impede pain signaling or enhance analgesic effects.
- Rare hereditary syndromes demonstrate complete pain insensitivity due to genetic mutations.
Purpose of the Study:
- To review genetic variants influencing pain perception and response to analgesics.
- To identify genes associated with pain insensitivity and reduced pain.
- To explore the role of genetic factors in clinical pain therapy.
Main Methods:
- Review of identified genetic variants and their association with pain.
- Analysis of genes involved in nociceptive processing and drug metabolism.
- Examination of hereditary sensory and autonomic neuropathy (HSAN) syndromes and channelopathies.
Main Results:
- Thirteen variants in the SCN9A gene cause channelopathy-associated insensitivity to pain.
- Mutations in various genes lead to Hereditary Sensory and Autonomic Neuropathy (HSAN) I-V syndromes.
- Frequent variants in OPRM1, COMT, GCH1, TRPV1, and MC1R genes are linked to reduced pain sensitivity or altered analgesic responses.
- CYP2D6 gene amplifications affect opioid metabolism, while ABCB1 variants influence fentanyl's respiratory effects.
Conclusions:
- A defined set of genetic variants can prevent pain or enhance analgesia.
- Understanding these genetic factors is crucial for personalized pain management.
- Further research will elucidate the extent of genetic influence on pain and its clinical applications.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:44Nociception
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...